Drug Trial Radar · NCT06978920
A Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of NCR201 in the Treatment of Subjects With Parkinson's Disease
Last checked: Nov 20, 2026Latest source record: Aug 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Jun 6, 2025
Primary completion
Jul 1, 2026
Study completion Dec 1, 2028
Sponsor
- Lead sponsor
- Nuwacell Biotechnologies Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy that NCR201 has on Parkinson's disease (PD) patients.
Conditions
- Parkinson Disease
Interventions
Allogeneic dopaminergic neural precursor cell(NCR201)Drug
Bilateral implantation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events.Time frame: Within 24 weeks post-transplantation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of USTC
Hefei, Anhui, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.